U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...